SURGE Therapeutics

SURGE Therapeutics is a Cambridge, MA–based biotech company developing an *intraoperative* immunotherapy platform that delivers extended‑release cancer immunotherapies directly into the surgical wound at the time of tumor resection to reduce recurrence and metastasis[3][2]. The company’s lead approach uses a biodegradable hydrogel (SURGERx) formulated to concentrate immunomodulators at the resection site and sustain local exposure, with multiple programs advancing toward clinical testing[3][1].

High-Level Overview

• Mission: To make intraoperative immunotherapy a standard part of cancer surgery so patients receive localized, time‑sensitive immune activation at the moment of tumor resection to prevent recurrence and improve survival[3][2].
  - Investment philosophy (not applicable—SURGE is a portfolio company / biotech developer).
  - Key sectors: Oncology biologics/medical devices intersection—local drug delivery, immunotherapy, surgical adjuncts[3][2].
  - Impact on the startup/clinical ecosystem: SURGE reframes surgical oncology by integrating biomaterials and immuno‑oncology, potentially creating a new class of perioperative therapeutics and new clinical pathways for combining surgery with localized immunomodulation[3][2].

For SURGE as a portfolio company:

• What product it builds: An optimized biodegradable hydrogel platform (SURGERx) that delivers and sustains release of immunotherapies directly into the tumor resection cavity during surgery[3][2].
  - Who it serves: Patients undergoing surgical resection for solid tumors and the clinicians treating them (surgical oncologists, urologists, etc.)[3][3].
  - What problem it solves: Addresses high post‑surgical recurrence rates by delivering a focused, sustained immunotherapeutic insult at the time and place most likely to eliminate residual microscopic disease and reduce metastatic seeding[3][2].
  - Growth momentum: SURGE has progressed from Series A financing to a Series B and has secured IND acceptance from the FDA for a Phase 1/2a study of SURGERx with resiquimod in non‑muscle invasive bladder cancer, indicating clinical and financial traction[4][1].

Origin Story

• Founding year & roots: SURGE grew out of academic research at Harvard Medical School and launched publicly in 2022 with initial financing to translate an intraoperative hydrogel concept into the clinic[2][3].
  - Founders and background: Public materials cite leadership including founder/CEO Michael Goldberg and scientific roots in Harvard research that identified surgery‑induced immune suppression as a window for intervention[2][3].
  - How the idea emerged: Preclinical work showed surgery can provoke inflammation and transient immune suppression that enables residual cancer cells to regrow; the team developed a biodegradable hydrogel to deliver immunostimulatory agents exactly when and where they’re needed—during the resection procedure[3][2].
  - Early traction / pivotal moments: Series A funding (~$26M) at launch, subsequent Series B (~$32M) and IND acceptance by the FDA for the bladder cancer program are key milestones toward clinical validation[2][4][1].

Core Differentiators

• Timing and location focus: Delivers therapy intraoperatively—*at the moment of tumor removal*—rather than systemically or post‑op, exploiting a critical biological window[3][2].
  - Localized, sustained delivery: Biodegradable hydrogel enables high local concentration and prolonged exposure while limiting systemic toxicity compared with systemic immunotherapy[3][2].
  - Platform versatility: The hydrogel can be formulated with different immunomodulators (e.g., resiquimod/TLR agonists) to address multiple tumor types and indications[1][3].
  - Clinical pathway integration: Designed to be applied during standard surgical workflows (injectable into the resection cavity), which may ease adoption versus entirely new treatment modalities[3].
  - Evidence and momentum: Transitioning from preclinical to human testing with FDA IND acceptance and active fundraising demonstrates translational progress and commercial viability[4][1].

Role in the Broader Tech / MedTech Landscape

• Trend alignment: SURGE sits at the intersection of biomaterials, localized drug delivery, and immuno‑oncology—fields that are converging to reduce systemic toxicity while improving efficacy[3][2].
  - Why timing matters: High rates of post‑surgical recurrence and growing understanding of perioperative immune biology create a clear unmet need for intraoperative interventions[2][3].
  - Market forces in favor: Rising adoption of combination immunotherapies, increased investment in surgical adjunct technologies, and payer/clinician interest in durable reductions in recurrence support commercial potential[3][4].
  - Ecosystem influence: If successful, SURGE could catalyze new clinical trials, spur competitors and partners (biotech, surgical device firms, and pharma) to develop intraoperative biologics, and change standard‑of‑care pathways in surgical oncology[3][2].

Quick Take & Future Outlook

• Near term: Expect continued clinical development for lead programs (e.g., the IND‑cleared bladder cancer study), additional INDs for other tumor indications, and further partnership or licensing activity as clinical data emerge[4][1].
  - Mid term: Positive safety and early efficacy readouts could position SURGE to run larger registrational studies and attract strategic partners (large oncology pharma or surgical device companies) to scale commercial deployment[4][3].
  - Risks & determinants: Clinical proof of durable recurrence reduction and manageable safety are critical; regulatory acceptance of intraoperative biologics and surgeon adoption will determine commercial pace[1][4].
  - Broader impact: If the approach validates the concept that targeted intraoperative immunomodulation reduces recurrence, SURGE could redefine the perioperative standard of care and create a new product category for oncology therapeutics[3][2].

Key sources: SURGE Therapeutics corporate site and news releases; coverage in Chemical & Engineering News and patent/clinical listing summaries documenting the hydrogel platform, funding history, and IND/clinical progress[3][4][2][1].